The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

In patients with chronic liver disease, including PBC, ursodeoxycholic acid shows promise as an adjunctive therapy for COVID-19 infection.

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

Report with the AI impact on market trends- The global ursodeoxycholic acid market size is estimated to grow by USD 463.2 ...

The global market for primary sclerosing cholangitis (PSC) is on an impressive growth trajectory, with forecasts estimating a ...